Table 4.
Data used in a meta-analysis to assign average doses in each CYP2C9 genotype when simulating ‘genotype-related dosing’
| Average dose in each genotype* | Percentage of subjects with each genotype | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | n | * 1/* 1 | * 1/* 2 | * 1/* 3 | * 2/* 2 | * 2/* 3 | * 3/* 3 | * 1/* 1 | * 1/* 2 | * 1/* 3 | * 2/* 2 | * 2/* 3 | * 3/* 3 |
| Siguret et al. [23] | 126 | 3.1 (1.4) | 2.7 (1.3) | 2.9 (1.1) | – | 2.3 (1.8) | – | 63.5 | 15.9 | 14.3 | 1.6 | 4.8 | – |
| Kamali et al. [9] | 119 | 4.06 (1.72) | 3.63 (1.78) | 2.7 (1.36) | – | – | – | 62.2 | 25.2 | 12.6 | – | – | – |
| Aithal et al. [16] | 155 | 4.68 (2.1) | 3.7 (1.9) | 2.7 (1.3) | – | – | – | 65.2 | 20.6 | 14.2 | – | – | – |
| Taube et al. [19] | 561 | 5.01 (2.43) | 4.31 (1.94) | 3.97 (1.79) | 3.04 (1.29) | 4.09 (2.09) | – | 69.9 | 19.1 | 9.4 | 0.5 | 1.1 | – |
| Loebstein et al. [11] | 156 | 6.5 (3.2) | 5.2 (2.4) | 1.6 (0.6) | – | – | – | 69.2 | 17.9 | 12.8 | – | – | – |
| Higashi et al. [17] | 185 | 5.63 (2.56) | 4.88 (2.57) | 3.32 (0.94) | 4.07 (1.48) | 2.34 (0.35) | 1.6 (0.81) | 68.6 | 15.1 | 9.7 | 2.2 | 1.6 | 2.7 |
| Margaglioni et al.[18] | 180 | 6.7 (2.9) | 5.2 (2.2) | 3.8 (2.0) | – | – | – | 48.9 | 34.4 | 15.6 | – | 1.1 | – |
*
Mean (standard deviation).